BioCardia (BCDA) Net Cash Flow (QoQ) (2010 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 304.92% |
| Mar 31, 2026 | 44.64% |
| Dec 31, 2025 | -164.80% |
| Sep 30, 2025 | 13,793.55% |
| Jun 30, 2025 | 102.18% |
| Mar 31, 2025 | 44.43% |
| Dec 31, 2024 | -172.93% |
| Sep 30, 2024 | 643.43% |
| Jun 30, 2024 | 406.49% |
| Mar 31, 2024 | 78.96% |
| Dec 31, 2023 | 70.36% |
| Sep 30, 2023 | -347.46% |
| Jun 30, 2023 | 77.97% |
| Mar 31, 2023 | -460.06% |
| Dec 31, 2022 | 135.75% |
| Sep 30, 2022 | -47.95% |
| Jun 30, 2022 | 55.27% |
| Mar 31, 2022 | 2.45% |
| Dec 31, 2021 | -13.60% |
| Sep 30, 2021 | 10.27% |